NASDAQ:INFI

Infinity Pharmaceuticals Competitors

$2.78
-0.07 (-2.46 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.69
Now: $2.78
$2.94
50-Day Range
$2.60
MA: $3.17
$3.64
52-Week Range
$0.78
Now: $2.78
$5.98
Volume1.41 million shs
Average Volume3.58 million shs
Market Capitalization$246.42 million
P/E RatioN/A
Dividend YieldN/A
Beta2.4

Competitors

Infinity Pharmaceuticals (NASDAQ:INFI) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying INFI stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Infinity Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Institutional and Insider Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Amgen and Infinity Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.39$7.84 billion$14.8217.49
Infinity Pharmaceuticals$3.05 million80.79$-47,060,000.00($0.83)-3.35

Amgen has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Amgen and Infinity Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen091402.61
Infinity Pharmaceuticals02602.75

Amgen presently has a consensus target price of $261.1429, suggesting a potential upside of 0.77%. Infinity Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 223.74%. Given Infinity Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Infinity Pharmaceuticals is more favorable than Amgen.

Profitability

This table compares Amgen and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Infinity Pharmaceuticals-2,592.65%-1,358.77%-81.85%

Volatility & Risk

Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.

Summary

Amgen beats Infinity Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Volatility & Risk

Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Infinity Pharmaceuticals-2,592.65%-1,358.77%-81.85%

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Gilead Sciences and Infinity Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.72$5.39 billion$6.1410.81
Infinity Pharmaceuticals$3.05 million80.79$-47,060,000.00($0.83)-3.35

Gilead Sciences has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Gilead Sciences and Infinity Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191302.52
Infinity Pharmaceuticals02602.75

Gilead Sciences presently has a consensus price target of $97.68, indicating a potential upside of 47.15%. Infinity Pharmaceuticals has a consensus price target of $9.00, indicating a potential upside of 223.74%. Given Infinity Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Infinity Pharmaceuticals is more favorable than Gilead Sciences.

Summary

Gilead Sciences beats Infinity Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Infinity Pharmaceuticals (NASDAQ:INFI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Infinity Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Infinity Pharmaceuticals-2,592.65%-1,358.77%-81.85%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Infinity Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Infinity Pharmaceuticals02602.75
Vertex Pharmaceuticals042112.88

Infinity Pharmaceuticals presently has a consensus target price of $9.00, suggesting a potential upside of 223.74%. Vertex Pharmaceuticals has a consensus target price of $293.2083, suggesting a potential upside of 33.18%. Given Infinity Pharmaceuticals' higher probable upside, analysts clearly believe Infinity Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

Infinity Pharmaceuticals has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

46.7% of Infinity Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 13.8% of Infinity Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Infinity Pharmaceuticals and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Infinity Pharmaceuticals$3.05 million80.79$-47,060,000.00($0.83)-3.35
Vertex Pharmaceuticals$4.16 billion13.69$1.18 billion$4.2951.32

Vertex Pharmaceuticals has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Infinity Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Regeneron Pharmaceuticals and Infinity Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Infinity Pharmaceuticals02602.75

Regeneron Pharmaceuticals presently has a consensus target price of $644.1739, suggesting a potential upside of 27.71%. Infinity Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 223.74%. Given Infinity Pharmaceuticals' higher probable upside, analysts clearly believe Infinity Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Infinity Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.87$2.12 billion$21.4723.49
Infinity Pharmaceuticals$3.05 million80.79$-47,060,000.00($0.83)-3.35

Regeneron Pharmaceuticals has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Infinity Pharmaceuticals-2,592.65%-1,358.77%-81.85%

Summary

Regeneron Pharmaceuticals beats Infinity Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Analyst Ratings

This is a summary of current recommendations for Biogen and Infinity Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5141202.23
Infinity Pharmaceuticals02602.75

Biogen presently has a consensus target price of $303.3103, suggesting a potential upside of 11.02%. Infinity Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 223.74%. Given Infinity Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Infinity Pharmaceuticals is more favorable than Biogen.

Profitability

This table compares Biogen and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Infinity Pharmaceuticals-2,592.65%-1,358.77%-81.85%

Institutional & Insider Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Biogen and Infinity Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.89$5.89 billion$33.578.14
Infinity Pharmaceuticals$3.05 million80.79$-47,060,000.00($0.83)-3.35

Biogen has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500.

Summary

Biogen beats Infinity Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Alexion Pharmaceuticals and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Infinity Pharmaceuticals-2,592.65%-1,358.77%-81.85%

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Alexion Pharmaceuticals and Infinity Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017412.27
Infinity Pharmaceuticals02602.75

Alexion Pharmaceuticals presently has a consensus target price of $153.4286, indicating a potential downside of 7.87%. Infinity Pharmaceuticals has a consensus target price of $9.00, indicating a potential upside of 223.74%. Given Infinity Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Infinity Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Risk and Volatility

Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500.

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Infinity Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.37$2.40 billion$9.7417.10
Infinity Pharmaceuticals$3.05 million80.79$-47,060,000.00($0.83)-3.35

Alexion Pharmaceuticals has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats Infinity Pharmaceuticals on 9 of the 15 factors compared between the two stocks.


Infinity Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$259.14-1.2%$149.21 billion$23.36 billion20.90Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.38-0.6%$83.58 billion$22.45 billion68.43Analyst Report
Analyst Revision
News Coverage
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$220.16-0.4%$56.98 billion$4.16 billion27.80Analyst Report
Analyst Revision
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$504.42-0.9%$54.04 billion$7.86 billion18.44Analyst Report
Biogen logo
BIIB
Biogen
1.9$273.20-1.5%$41.62 billion$14.38 billion9.04Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$166.54-0.6%$36.79 billion$4.99 billion38.91News Coverage
Seagen logo
SGEN
Seagen
1.7$144.76-0.5%$26.25 billion$916.71 million56.99Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.62-1.5%$21.24 billion$876.29 million-56.84Analyst Upgrade
Incyte logo
INCY
Incyte
1.7$84.57-2.2%$18.59 billion$2.16 billion-53.87
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$136.03-1.0%$15.96 billion$219.75 million-17.37Analyst Report
News Coverage
Gap Up
Novavax logo
NVAX
Novavax
1.4$208.15-6.4%$15.37 billion$18.66 million-39.88Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.45-0.2%$14.45 billion$1.70 billion18.18Analyst Report
News Coverage
Repligen logo
RGEN
Repligen
1.5$211.99-0.0%$11.61 billion$270.24 million258.52Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$207.58-1.8%$9.25 billion$1.45 billion19.64
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.16-1.4%$9.09 billion$788.10 million103.40Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Exelixis logo
EXEL
Exelixis
1.9$24.51-3.1%$7.67 billion$967.78 million51.06Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.83-1.6%$6.71 billion$195.99 million292.69
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.16-3.0%$5.80 billion$1.12 billion85.75Analyst Report
Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.76-2.1%$4.03 billion$806.43 million-9.46Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.62-3.4%$3.52 billion$1.11 billion21.10High Trading Volume
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.16-0.5%$3.21 billion$1.17 billion-43.83Insider Selling
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.29-1.1%$3.16 billion$36.13 million-67.60
OPKO Health logo
OPK
OPKO Health
1.9$4.13-1.7%$2.77 billion$901.90 million-22.94
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.79-1.2%$2.59 billion$182.24 million-8.51Analyst Upgrade
Insider Selling
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$146.76-0.5%$2.44 billion$120.28 million-148.24Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$26.61-2.3%$2.05 billion$638.60 million-10.23Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$126.33-4.1%$2.02 billionN/A-11.41News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.11-3.6%$1.97 billion$48.83 million-14.62
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.66-0.5%$1.72 billion$428.41 million15.45Analyst Upgrade
News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.53-1.9%$1.66 billion$102.43 million-19.22Analyst Upgrade
Codexis logo
CDXS
Codexis
1.3$22.89-1.4%$1.47 billion$68.46 million-65.40Analyst Report
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.32-1.2%$1.46 billion$82.27 million-17.85News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.98-0.8%$1.21 billion$261.02 million6.11
MannKind logo
MNKD
MannKind
1.4$4.23-1.7%$1.05 billion$63.04 million-20.14Increase in Short Interest
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.94-21.8%$1.01 billion$35.22 million-6.53
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.67-2.0%$937.69 million$3.57 million-10.61
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.55-0.7%$908.31 million$227.19 million45.97Analyst Downgrade
Curis logo
CRIS
Curis
1.3$9.82-5.0%$898.72 million$10 million-11.98News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.34-0.2%$884.22 millionN/A0.00
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88-0.8%$704.45 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.80-2.9%$689.77 million$252 million-2.13
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17-0.9%$682.20 million$150,000.00-4.53News Coverage
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55-2.0%$603.93 million$59.29 million-23.67Increase in Short Interest
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.67-1.9%$592.69 million$143.01 million-1.08
Agenus logo
AGEN
Agenus
1.6$2.68-4.1%$547.53 million$150.05 million-2.45
Verastem logo
VSTM
Verastem
1.3$2.71-0.4%$465.22 million$17.46 million-1.92
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.91-0.7%$447.35 million$109.33 million-2.14
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.96-4.1%$446.17 million$22.27 million-3.90Analyst Revision
News Coverage
Geron logo
GERN
Geron
1.4$1.40-0.0%$445.94 million$460,000.00-4.00Decrease in Short Interest
XOMA logo
XOMA
XOMA
1.5$35.44-1.6%$398.98 million$18.37 million-31.93Increase in Short Interest
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.